Werewolf Therapeutics (HOWL) Notes Payables (2023 - 2026)

Werewolf Therapeutics (HOWL) posted quarterly Notes Payables of $28.8 million for Q1 2026, up 2.11% on a QoQ basis from $28.2 million in Q4 2025.

Werewolf Therapeutics (HOWL) Notes Payables (2023 - 2026) Analysis & Trends

Werewolf Therapeutics has reported Notes Payables for 4 years, with the latest figure at $28.8 million in Q1 2026.

Notes Payables for Q1 2026 came in at $28.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $28.8 million (changed N/A YoY), and the FY2025 annual result was $28.2 million, changed N/A from the prior year.
Notes Payables advanced to $28.8 million in Q1 2026, from $28.2 million in the prior quarter.
Over five years, Notes Payables peaked at $28.8 million in Q1 2026 and troughed at $1.7 million in Q3 2023.
A 4-year average of $12.2 million and a median of $6.7 million in 2023 frame the typical range for Notes Payables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Werewolf Therapeutics	43.94 Mn	43.94 Mn	-

Download Data